Crime Corporate Fraud

More

  • Jan 8- A federal appeals court on Friday set back Bank of New York Mellon Corp's effort to recoup $312 million it lent to Sentinel Management Group Inc, a money manager that collapsed in 2007 and whose former chief is now in prison for fraud. The 7th U.S. Circuit Court of Appeals in Chicago said a lower court judge reviewing bankruptcy trustee Frederick Grede's...

  • JPMorgan's Dimon, others defeat Madoff fraud appeal Wednesday, 6 Jan 2016 | 11:11 AM ET

    NEW YORK, Jan 6- JPMorgan Chase& Co shareholders cannot pursue a lawsuit to force Chief Executive Jamie Dimon and other officials to pay damages to the largest U.S. bank for their alleged ignorance of red flags signaling Bernard Madoff's Ponzi scheme, a federal appeals court ruled on Wednesday. The Steamfitters Local 449 Pension Fund in Pittsburgh and the...

  • Dec 30- KaloBios Pharmaceuticals Inc, a biotechnology company that fired Chief Executive Martin Shkreli earlier this month after his arrest on charges of securities fraud, filed for Chapter 11 bankruptcy on Tuesday. Shkreli gained notoriety when, as the chief executive of Turing Pharmaceuticals, he raised the price of a drug used to treat a dangerous...

  • NEW YORK, Dec 28- KaloBios Pharmaceuticals Inc said on Monday that two directors had resigned in the wake of the arrest of former CEO Martin Shkreli on securities fraud charges earlier this month. Tom Fernandez and Marek Biestek resigned from the KaloBios board on Sunday, the company said a regulatory filing. The departures came more than a week after the company...

  • SAN FRANCISCO, Dec 23- Palantir Technologies, a data analytics and security company that helps government agencies track down terrorists and uncover financial fraud, said on Wednesday it has raised $880 million in its latest financing round. The Palo Alto, California- based company raised another $200 million on top of the $679.8 million since the round began...

  • Kalobios says Nasdaq to delist stock Wednesday, 23 Dec 2015 | 4:18 PM ET

    Dec 23- Kalobios Pharmaceuticals Inc said on Wednesday it had been notified by Nasdaq that it will delist the stock using its "discretionary" authority. The drugmaker last week said it had fired Martin Shkreli as its chief executive on Dec. 17, the day he was arrested on charges of a securities fraud. Shkreli, who has become the poster child for the issue of soaring...

  • Ex-Adelphia CEO loses early prison release bid Wednesday, 23 Dec 2015 | 7:43 AM ET

    John Rigas lost a bid for early release from prison due to his diagnosis of terminal cancer.

  • Dec 22- Turing Pharmaceuticals said on Tuesday it is seeking a new chief executive to replace Martin Shkreli, the price-gouging entrepreneur who is facing U.S. charges of securities fraud, and will cut jobs in a restructuring. On Monday, KaloBios Pharmaceuticals said Shkreli was "terminated" as CEO and had resigned from the board. Shkreli gained notoriety when, as...

  • NEW YORK, Dec 22- John Rigas, the former chief executive of Adelphia Communications Corp who is serving a 12- year sentence for his role in a fraud that led to the cable company's collapse, on Tuesday lost a bid for early release from prison due to his diagnosis of terminal cancer. Rigas and his son, Timothy Rigas, Adelphia's former chief financial officer, were found...

  • UPDATE 3-KaloBios fires Shkreli as CEO Monday, 21 Dec 2015 | 1:23 PM ET

    Dec 21- Drugmaker KaloBios Pharmaceuticals Inc said it fired Martin Shkreli as chief executive on Dec. 17, the day he was arrested on charges of a securities fraud. Shkreli was arrested last week for engaging in what U.S. prosecutors said was a Ponzi-like scheme at his former hedge fund MSMB Capital Management and Retrophin Inc, a company he headed before he took...

  • UPDATE 2-KaloBios removes Shkreli as CEO Monday, 21 Dec 2015 | 11:31 AM ET

    Dec 21- Drugmaker KaloBios Pharmaceuticals Inc said it removed Martin Shkreli as chief executive on Dec. 17, the day he was arrested on charges of a securities fraud. Shkreli, who stepped down as CEO of private drugmaker Turing Pharmaceuticals Inc, also resigned from KaloBios' board of directors. Shkreli lost control of his Twitter account to hackers on Sunday,...

  • NEW YORK, Dec 21- JPMorgan Chase& Co has agreed to pay $150 million to resolve a securities fraud lawsuit by investors suing the bank over its "London Whale" trading scandal, which caused a $6.2 billion loss. Shareholders accused JPMorgan of knowingly hiding increased risks at the Chief Investment Office, including on an April 13, 2012, conference call when...

  • UPDATE 1-KaloBios removes Shkreli as CEO Monday, 21 Dec 2015 | 10:05 AM ET

    Dec 21- Drugmaker KaloBios Pharmaceuticals Inc said it removed Martin Shkreli as chief executive on Dec. 17, the day he was arrested on charges of a securities fraud. Shkreli, who stepped down as CEO of private drugmaker Turing Pharmaceuticals Inc, also resigned from KaloBios' board of directors. Shkreli lost control of his Twitter account to hackers on Sunday,...

  • KaloBios terminates Shkreli as CEO Monday, 21 Dec 2015 | 9:44 AM ET

    Dec 21- Drugmaker KaloBios Pharmaceuticals Inc said it terminated Martin Shkreli as chief executive on Dec. 17, the day he was arrested on charges of securities fraud. Shkreli, who stepped down as CEO of private drugmaker Turing Pharmaceuticals Inc, also resigned from his position on KaloBios' board of directors. Shkreli was arrested for engaging in what U.S....

  • Dec 20- Martin Shkreli, the pharmaceutical executive facing U.S. charges of securities fraud, lost control of his Twitter account to hackers on Sunday, hours after he took to Twitter to plead his innocence, his spokesman said. "It was hacked," Craig Stevens, a spokesman for the former chief executive of Turing Pharmaceuticals, said in an email. "We have been working with...

  • Ex-pharma CEO Shkreli calls charges 'baseless' Sunday, 20 Dec 2015 | 5:02 PM ET
    Martin Shkreli, CEO of Turing Pharmaceutical, is brought out of 26 Federal Plaza by law enforcement officials after being arrested for securities fraud on Dec. 17, 2015, in New York City.

    Bad-boy ex-pharmaceutical company CEO Martin Shkreli says fraud allegations against him are "baseless and without merit."

  • Dec 18- Martin Shkreli, the poster boy for large prescription drug price increases, has stepped down as chief executive of Turing Pharmaceuticals, the company said on Friday, following his arrest for securities fraud earlier this week. They co-founded another pharmaceutical company, Retrophin Inc, that is at the center of the securities fraud charges against...

  • Dec 18- Martin Shkreli, the poster boy for prescription drug price increases who was arrested for securities fraud this week, has stepped down from his post as chief executive officer of Turing Pharmaceuticals Inc, the company said on Friday. Shkreli has been under investigation for securities fraud related to hedge fund MSMB Capital Management and...

  • Dec 18- Privately held drugmaker Turing Pharmaceuticals Inc is close to replacing Chief Executive Martin Shkreli, the Wall Street Journal reported on Friday, a day after the FBI arrested him on charges of securities fraud. Shkreli was charged in a federal indictment on Thursday related to his time managing hedge fund MSMB Capital Management and CEO of...

  • Turing Pharma close to replacing CEO Shkreli - WSJ Friday, 18 Dec 2015 | 11:21 AM ET

    Dec 18- Privately held drugmaker Turing Pharmaceuticals Inc is close to replacing Chief Executive Martin Shkreli, the Wall street Journal reported on Friday, a day after the FBI arrested him on charges of securities fraud. Shkreli was charged in a federal indictment on Thursday related to his time managing hedge fund MSMB Capital Management and CEO of...